Pharmacokinetic evaluation and therapeutic activity of bendamustine in B-cell lymphoid malignancies

Expert Opinion on Drug Metabolism and Toxicology

Volumn 8, Issue 11, 2012, Pages 1455-1468

  Korycka Wołowiec, Anna ^a   Robak, Tadeusz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Bendamustine; Clinical efficacy; Lymphoid malignancies; Mechanism of action; Metabolites; Pharmacokinetic properties

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DEXAMETHASONE; LENALIDOMIDE; MITOXANTRONE; PREDNISONE; RITUXIMAB; THALIDOMIDE; VINCRISTINE;

AEROBIC METABOLISM; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONSTIPATION; DISEASE COURSE; DNA STRAND BREAKAGE; DNA SYNTHESIS; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TRANSFORMATION; EVALUATION; FATIGUE; FEVER; FIRST PASS EFFECT; FOLLOW UP; HUMAN; HYDROLYSIS; HYPERGLYCEMIA; LEUKOPENIA; M PHASE CELL CYCLE CHECKPOINT; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; REVIEW; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADMINISTRATION, INTRAVENOUS; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; DRUG EVALUATION; EUROPE; HUMANS; JAPAN; LYMPHOMA, B-CELL; LYMPHOMA, MANTLE-CELL; NITROGEN MUSTARD COMPOUNDS; UNITED STATES;

EID: 84867549054     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2012.723690     Document Type: Review

References (79)

1. Ożegowski W, Krebs D. IMET3393 ([1methyl-5-bis-(b-chloroethyl)- aminobenz-imidazolyl-(2)]-butyric acid hydrochloride, a new cytotoxic agent from among the series of benzimidazole mustard compounds [in German]. Zbl Pharm 1971;110:1013-19
2. Anger G, Hesse P, Baufeld H. Treatment of multiple myeloma with a new cytostatic agent: Gamma-1-methyl-5-bis- (b-chloroethyl)-amino-benzimidazalyl- (2)]-butyric acid hydrochloride. Dtsch Med Wochenschr 1969; 94:2495-500
3. Hartmann M, Zimmer C. Investigation of cross-link formation in DNA by the alkylating cytostatic IMET 3106, 3393 and 3943. Biochim Biophys Acta 1972;287:386-9
4. Herold M, Keinert K, Anger G, et al. Risk-adapted combined radiotherapy and chemotherapy for Hodgkin's diseaseresults of a pilot study. Oncology 1992;15:502-5
5. Heider A, Kress M, Niederle N. Bendamustine as second line therapy in patients with relapsed low-grade non-Hodgkin's lymphoma and multiple myeloma [in German]. Tumor Diagn Ther 1997;18:71-5
6. Cheson BD, Rummel MJ. Bendamustine: Rebirth of an old drug. J Clin Oncol 2009;27:1492-501
7. Leoni LM. Bendamustine: Rescue of effective antineoplastic agent from the mid-twentieth century. Semin Oncol 2011;48(Suppl 1):4-11
8. Schmittel A, Knoedler M, Hortig P, et al. Phase II trial of second-line bendamustine chemotherapy in relapsed small-cell lung cancer patients. Lung Cancer 2007;55:109-13
9. Loibl S, Murmann C, Schwedler K, et al. Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial. Cancer Chemother Pharmacol 2009;63:953-8
10. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study. J Clin Oncol 2012;30(Suppl):abstract 3
11. Zaborowska A, Cebula B, Franiak Pietryga I, et al. The influence of bendamustine used either alone or in combination with purine nucleoside analogues on the viability and apoptosis of chronic lymphocytic leukemia cells in culture in vitro. Acta Haematol Pol 2009;40:887-98
12. Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory and alkylator refractory, indolent, and transformed non-Hodgkin's lymphoma: Results of a phase II multicenter single-agent study. J Clin Oncol 2008;26:204-10
13. Bergmann MA, Goebeler ME, Herold M, et al. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase I/II study of the German CLL Study Group. Haematologica 2005;90:1357-64
14. Hartmann JT, Mayer F, Schleicher J, et al. Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: A noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001). Cancer 2007; 110:861-6
15. Elefante A, Czuczman MS. Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Am J Health Syst Pharm 2010;67:713-23
16. Knauf WU, Lissichkov T, Aldaound A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27:4378-84
17. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005; 23:3383-9
18. Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. Cancer 2010;116:106-14
19. Cheson BD, Friedberg JW, Kahl BS, et al. Bendamustine produces durable responses with an acceptable safety profile in patients with rituximabrefractory indolent non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2010;10:452-7
20. Leoni LM, Baliey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanism features compared with other alkylating agent. Clin Cancer Res 2008;14:309-17
21. Zong WX, Ditsworth D, Bauer DE, et al. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev 2004;45:1429-36
22. Roue G, Lopez-Guerra M, Milpied P, et al. Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling. Clin Cancer Res 2008;14:6907-15
23. Teichert J, Sohr R, Baumann F, et al. Synthesis and characterization of some new phase II metabolites of alkylator bendamustine and their identification in human bile, urine and plasma from patients with cholangiocarcinoma. Drug Metab Dispos 2005;33:984-92
24. Teichert J, Baumann F, Chao Q, et al. Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride. Cancer Chemother Pharmacol 2007; 59:759-70
25. Herold M, Schulze A, Niederweiser D, et al. Bendamustine, vincristine, prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle-cell lymphoma: Result of the randomized phase III trials (OSHO19). J Cancer Res Clin Oncol 2006; 132:105-12
26. Gandhi V. Metabolism and mechanism of action of bendamustine: Rationales for combination therapy. Semin Oncol 2002;29(Suppl 13):4-11
27. Ogura M, Uchida M, Taniwaki M, et al. Phase I and pharmacokinetic study of bendamustine in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci 2010;101:2054-8
28. Tageja N, Nagi J. Bendamustine: something old, something new. Cancer Chemother Pharmacol 2010;66:413-23
29. Ohmachi K, Ando K, Ogura M, et al. Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci 2010;101:2059-64
30. Haase D, Preiss R, Sohr R. Untersuchungen zur Plasmaeiweissbindung von Bendamustine (Cytostasan) und Ambazon. Z Klein Med 1990;45:1267-72
31. Preiss R, Sohr R, Matthias M, et al. The pharmacokinetics of bendamustine (Cytostasan) in humans. Pharmazie 1985;40:782-4
32. Chovan JP, Li F, Yu E, Ring SC. Metabolic profile of [(14)C] bendamustine in rat urine and bile: Preliminary structural identification of metabolites. Drug Metab Dispos 2007;35:1744-55
33. Ujjani Ch, Cheson BD. Bandamustine in chronic lymphocytic leukemia and non-Hodgkin lymphoma. Expert Rev Anticancer Ther 2010;10:1353-65
34. Teichert J, Sohr R, Hennong L, et al. Identification and quantitation of the Nacetyl-L-cysteine S-conjugates of bendamustine and its sulfoxides in human bile after administration of bendamustine hydrochloride. Drug Metab Dispos 2009;37:292-301
35. Debbelamn AC, Jansen RS, Rosing H, et al. Metabolites profiling of bendamustine in urine of cancer patients after administration of [ 14C]bendamustine. Drug Metab Dispos 2012;40(7):1297-307
36. Owen JS, Melhem M, Passarell JA, et al. Bendamustine pharmacokinetic profile and exposure-response relationship in patients with indolent non-Hodgkin's lymphoma. Cancer Chemother Pharmacol 2010;66:1039-49
37. Rasscharet M, Schrijvers D, Van den Brande J, et al. A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors. Anticancer Drugs 2007;18:587-95
38. Rasscharet M, Schrijvers D, Van den Brande J, et al. A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumors. Br J Cancer 2007;96:1692-8
39. Garnock-Jones KP. Bendamustine. A review of its use in the management of indolent non-Hodgkin's lymphoma and mantle cell lymphoma. Drugs 2010; 70:1703-18
40. Schoffski P, Seelend G, Engel H, et al. Weekly administration of bendamustine: A phase I study in patients with advanced progressive solid tumors. Ann Oncol 2000;11:729-34
41. Schoffski P, Hagedorn T, Grunwald V, et al. Repeated administration of short infusion of bendamustine: A phase I study in patients with advanced progressive solid tumor. J Cancer Res Clin Oncol 2000;126:41-7
42. Ogura M, Ando K, Taniwaki M, et al. Feasibility and pharmacokinetics study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Cancer Sci 2011;102:1687-92
43. Lissitchkov T, Arnaudov G, Peytchev D, Merkle K. Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. J Cancer Res Clin Oncol 2006;132:99-104
44. Koppler H, Heymanns J, Pandorf A, Weide R. Bendamustine plus mitoxantrone - a new effective treatment for advanced chronic lymphocytic leukaemia: Results of a phase I/II study. Leuk Lymphoma 2004;45:911-13
45. Koppler H, Fuss H, Hurtz HJ, et al. Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): Results of a multicentre phase II study of the German CLL Study Group (GCLLSG). Br J Haematol 2012;158:238-41
46. Weide R, MergenthaleU, et al. Bendamustine/mitoxantrone/rituximab: A short remission induction chemoimmunotherapy for elderly patients with relapsed or refractory chronic lymphocytic leukemia. Leuk Lymphoma 2009;50:1468-74
47. Fischer K, Stilgenbauer S, Schweighofer CD, et al. Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): A multicentre phase II trial of the German CLL study group (GCLLSG). J Clin Oncol 2011;29:3559-66
48. Weide R, Pandorf A, Heymanns J, Koppler H. Bendamustine/Mitoxantrone/ Rituximab (BMR): A very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study. Leuk Lymphoma 2004;45:2445-9
49. Plosker GL, Carter NJ. Bendamustine: A review of its use in the management of indolent non-Hodgkin lymphoma. Drugs 2008;68:2645-60
50. Heider A, Niederle N. Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas. Anticancer Drugs 2001;12:725-9
51. Bremer K. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated lowgrade non-Hodgkin's-lymphomas. J Cancer Res Clin Oncol 2002; 128:603-9
52. Rigacci L, Puccini B, Cortelazzo S, et al. Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients -A multicenter retrospective study on behalf of the Italian Lymphoma Foundation. Ann Hematol 2012;91:1013-22
53. Fowler N. Kahl, BS, Lee P, et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: The phase II vertical study. J Clin Oncol 2011;29:3389-95
54. Ponisch W, Niederwieser D. Bendamustine in the treatment of multiple myeloma: Results and future perspectives. Semin Oncol 2002;29(Suppl 13):23-6
55. Knop S, Straka C, Haen M, et al. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 2005;90:1287-8
56. Damaj G, Malard F, Hulin C, et al. Efficacy of bendamustine in relapsed/refractory myeloma patients: Results from the French compassionate use program. Leuk Lymphoma 2012;53:632-4
57. Ponisch W, Mitrou PS, Merkle K, et al. Treatment of Bendamustine and Prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisone - a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol 2006; 132:205-12
58. Ponisch W, Rozanski M, Goldschmidt H, et al. Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: Results of a Phase I clinical trial. Br J Haematol 2008;143:191-200
59. Fenk R, Michael M, Zohren F, et al. Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma. Leuk Lymphoma 2007;48:2345-51
60. Ponisch W, Andrea M, Wagner I, et al. Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using in combination with bendamustine and prednisone. J Cancer Res Clin Oncol 2012;138:1405-12
61. Lentzsch S, O'Sullivan A, Kennedy RC, et al. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: Results of phase I/II open-label, dose escalation study. Blood 2012;119:4608-13
62. Klippstein A, Schneider CP, Sayer HG, Hoffken K. Pneumocystis carinii pneumonia as a complication of bendamustine monotherapy in a patient with advanced progressive breast cancer. J Cancer Res Clin Oncol 2003;129:316-19
63. Carter SJ, Bernstein SH, Friedberg JW, Barr PM. Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma. Leuk Res 2011;35:e223-4
64. Reinbolt RE, Alam S, Layman R, et al. Pneumocystis jiroveci Pneumonia in an Atypical Host. Clin Breast Cancer 2012; 12:138-41
65. Tageja N. Bendamustine: safety and Efficacy in the Management of Indolent Non-Hodgkins Lymphoma. Clinical Medicine Insights: Oncology 2011; 5:145-56
66. Malipatil B, Ganesan P, Sundersingh S, Sagar TG. Preliminary experience with the use of bendamustine: A peculiar skin rash as the commonest side effect. Hematol Oncol Stem Cell Ther 2011;4:157-60
67. Alamdari HS, Pinter-Brown L, Cassarino DS et al. Severe cutaneous interface drug eruption associated with bendamustine. Dermatol Online J 2010;16:1
68. Lambertini M, Del Mastro L, Gardin G, et al. Stevens-Johnson syndrome after treatment with bendamustine. Leuk Res 2012;36:153-4
69. Gavini A, Telang GH, Olszewski AJ. Generalized purpuric drug exanthem with hemorrhagic plaques following bendamustine chemotherapy in a patient with B-prolymphocytic leukemia. Int J Hematol 2012;95:311-14
70. Glance LE, Cumpston A, Kanate A, Remick SC. Bendamustine-associated hemolytic anemia. Annals of Pharmacotherapy 2009;43:1903-6
71. Cheson BD, Wendtner CM, Pieper A. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: Treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk 2010;10:21-7
72. Blumel S, Goodrich A, Martin Ch, Dang NH. Bendamustine: A novel cytotoxic agent for hematological malignancies. Clin J Oncol Nurs 2008;12:799-806
73. Robak T, Robak E. Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders. Expert Opin Investig Drugs 2012;21:921-47
74. Kreitman RJ, Arons E, Stetler-Stevenson M, Miller KB. Response of hairy cell leukemia to bendamustine. Leuk Lymphoma 2011;52:1153-6
75. Moskowitz AJ, Hamlin Jr PA, Gerecitano J, et al. Bendamustine is highly active in heavily pre-treated relapsed and refractory Hodgkin lymphoma and serves as a bridge to allogeneic stem cell transplant [ASH Annual Meeting Abstracts]. Blood 2009;114(Suppl 1):720
76. Magyari F, Simon Z, Barna S, et al. Successful administration of rituximab-bendamustine regimen in the relapse of Hodgkin lymphoma after autologous hemopoietic stem cell transplantation. Hematol Oncol 2011;30(2):98-100
77. Treon SP, Hanzis C, Tripsas C, et al. Bendamustine therapy in patients with relapsed or refractory Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011;11:133-5
78. Kalaycio M. Bendamustine: A new look at an old drug. Cancer 2009;115:473-9
79. Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008;26:4473-9